The AUS-NET trial commenced in 2022 and is running through to 2027.
Across the five Centres of Excellence—The Queen Elizabeth Hospital, Royal North Shore Hospital, Peter MacCallum Cancer Centre, The Royal Brisbane and Women’s Hospital, and Fiona Stanley Hospital—there are currently 151 patients enrolled in the trial. Of these, 69 participants are in the intervention group and 69 are receiving usual care, with approximately 11 patients having withdrawn due to unforeseen circumstances. A small number of additional patients are yet to be randomised.
Recruitment at The Royal Brisbane and Women’s Hospital was temporarily placed on hold following the resignation of the site nurse, Rebekah Orford, who has since transitioned into a new role. This site is now being supported by Carly Smith, with enrolments expected to recommence in February 2026.
Peter MacCallum Cancer Centre continues to participate in the AUS-NET trial, with Tiphany Catalan currently supporting the site while the previous site nurse, Jessica Demajo, extends her maternity leave for a further year.
The input of our neuroendocrine cancer community is so important in improving outcomes and quality of life. If you are interested in taking part in the AUS-NET clinical trial and are currently receiving care at one of the participating hospitals, please speak with your treating team to determine whether participation may be suitable for you.
If you have any questions about the trial or what participation involves, you are also welcome to contact NeuroEndocrine Cancer Australia to speak with Dana Hart or Kahlia Wolsley, who play a fundamental role in the delivery and coordination of the AUS-NET trial and are available to provide further information and support.
